Chemi-Verse™ CDK18/Cyclin Y Kinase Assay Kit

Catalog #
78888
$850 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ CDK18/Cyclin Y Kinase Assay is a luminescent assay designed to measure CDK18 (cyclin-dependent kinase 18)/Cyclin Y kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant CDK18/Cyclin Y complex, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Cell division protein kinase 18, PCTAIRE-motif protein kinase 3, Serine/threonine-protein kinase PCTAIRE-3, PCTAIRE3, PCTK3, Cyclin-dependent kinase 18, C10orf9, CBCP1, CFP1, Cyclin box protein 1, Cyclin fold protein 1, cyclin-X, CDK-18
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
100608 CDK18/Cyclin Y, GST-Tag Recombinant* 10 µg -80°C
79334 5x Kinase Assay Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  Rb Protein (2 mg/ml) 125 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
CDK18: Q07002; Cyclin Y: Q8ND76
Background

CDK18 (cyclin dependent kinase 18) is a member of the cyclin-dependent protein kinase family involved in cell cycle, transcription and splicing. CDK associates with cyclins, which induce a conformational change that results in a dramatic increase of kinase activity. Cyclin levels vary during the cell cycle, allowing cyclins to regulate CDK activity in the cell. Dissociation of the complex returns CDK to its basal activity, and CDK is degraded by ubiquitin mediated proteolysis. Lack of regulation in cell cycle can result in apoptosis and finally in cancer, neurodegenerative diseases (Alzheimer’s or Parkinson disease) and cardiovascular complications (stroke). The understanding of the mechanisms involved in cell cycle regulation, and its control via the use of small molecule inhibitors will open new therapeutic avenues for the treatment of cancer and neurodegenerative diseases.